Antibody-drug conjugates in HER2-positive breast cancer

Antibody-drug conjugates (ADCs) combine the high specificity of monoclonal antibodies with the high anti-tumor activity of small molecular cytotoxic payloads. The anti-tumor activity of ADCs is mainly achieved by the direct blocking of the receptor by monoclonal antibodies, direct action and bystand...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lixi, Zhang, Di, Liu, Binliang, Lv, Dan, Zhai, Jingtong, Guan, Xiuwen, Yi, Zongbi, Ma, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812658/
https://www.ncbi.nlm.nih.gov/pubmed/34935688
http://dx.doi.org/10.1097/CM9.0000000000001932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812658/
https://www.ncbi.nlm.nih.gov/pubmed/34935688
http://dx.doi.org/10.1097/CM9.0000000000001932

Ejemplares similares